Delivering Market Success for Pharma Partners

This document is a guide that outlines the evolving landscape of biologics and biosimilars in the pharmaceutical industry. It discusses the projected growth of biologics, expected to reach US$710.53 billion by 2030, and the biosimilars market, anticipated to grow to US$66.9 billion by 2028. The guide emphasizes the complexities and costs associated with developing these products, including the need for innovative drug delivery systems that accommodate self-administration and ensure patient safety. It details the importance of Quality by Design (QbD) processes in manufacturing to enhance product quality and minimize risks. The document also highlights the significance of collaboration between pharmaceutical companies and contract manufacturers to optimize development processes, reduce timelines, and ensure compliance with regulatory standards. Additionally, it addresses the challenges of scaling up production and the necessity for a robust supply chain strategy to meet the diverse needs of biologic therapies throughout their lifecycle.